C

Celcuity
D

CELC

50.450
USD
1.00
(2.02%)
مغلق
حجم التداول
43,102
الربح لكل سهم
-4
العائد الربحي
-
P/E
-15
حجم السوق
2,140,427,570
الأخبار المقالات

العنوان: Celcuity

القطاع: Healthcare
الصناعة: Biotechnology
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic propertiesare differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.